REG - Polarean Imaging PLC - Notice of Results

Polarean ImagingAnnouncement

15/08/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230815:nRSO2694Ja&default-theme=true

RNS Number : 2694J  Polarean Imaging PLC  15 August 2023

15 August 2023

Polarean Imaging Plc

("Polarean" or the "Company")

 

Notice of results

 

Polarean Imaging Plc (AIM: POLX), a commercial-stage medical device leader in
advanced MRI scanning of the lungs, confirms that it will be announcing its
half year results for the six months ended 30 June 2023 on Thursday, 7
September 2023.

 

Christopher von Jako, PhD, Chief Executive Officer, and Charles Osborne, Chief
Financial Officer, will be hosting a live online presentation relating to the
results via the Investor Meet Company platform on Friday, 15 September 2023 at
10am BST.

 

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your IMC dashboard up until 9am the day before
the meeting or in real time during the presentation.

 

Investors can sign up to Investor Meet Company for free and add to meet
Polarean Imaging Plc here
(https://www.investormeetcompany.com/polarean-imaging-plc/register-investor) .
Investors who already follow Polarean on the Investor Meet Company platform
will automatically be invited.

 

Whilst the Company may not be in a position to answer every question it
receives, it will address the most prominent within the confines of
information already disclosed to the market through regulatory notifications.
A recording of the presentation will be available on the Investor Meet Company
platform afterwards.

 

Enquiries:

 

  Polarean Imaging Plc                                       www.polarean.com / www.polarean-ir.com
 Christopher von Jako, PhD, Chief Executive Officer          Via Walbrook PR
 Charles Osborne, Chief Financial Officer

  Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)               +44 (0)20 7710 7600
 Nicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare Investment

 Banking)
 Nick Adams / Nick Harland (Corporate Broking)

 Walbrook PR         Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
 Anna Dunphy / Phillip Marriage          Mob: +44 (0)7876 741 001 / +44 (0) 7867 984 082

 

About Polarean (www.polarean.com)

 

The Company and its wholly owned subsidiary, Polarean, Inc. (together the
"Group") are revenue-generating, medical imaging technology companies
operating in the high-resolution medical imaging space. Polarean aspires to
revolutionise pulmonary medicine by bringing the power and safety of MRI to
the respiratory healthcare community in need of new solutions to evaluate lung
ventilation, diagnose disease, characterise disease progression, and monitor
response to treatment. By researching, developing, and commercialising novel
imaging solutions with a non-invasive and radiation-free functional imaging
platform. Polarean's vision is to help address the global unmet medical needs
of more than 500 million patients worldwide suffering with chronic respiratory
disease. Polarean is a leader in the field of hyperpolarisation science and
has successfully developed the first and only hyperpolarised MRI contrast
agent to be approved in the United States.   The company also commercialises
systems (such as the HPX hyperpolarisation system), accessories (such as
Xe-specific chest coils and phantoms) and FDA-cleared post-processing software
(to support ventilation defect analysis), to support fully integrated modern
respiratory imaging operations.

 

 

PLC-RNS-2318

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORDZGMRDDMGFZM